EUVIMEDEUVIMED entdecken
ValidierungsstudieKohortenstudieOpen Access · CC BY 4.0

Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study

Vincent Lanting, Emese Vágó, Erzsébet Horváth-Puhó, Frits Mulder, Marcello Di Nisio, Pieter W Kamphuisen, Lars Pedersen, Nick van Es, Henrik T Sørensen

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2024.10.021 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Vincent Lanting und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Net…. Hauptthemen laut MEDLINE: Neoplasms, Venous Thromboembolism, Decision Support Techniques. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Independent Research Fund Denmark, Karen Elise Jensens Fond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Guidelines recommend using risk assessment tools to identify ambulatory patients with cancer at high risk of venous thromboembolism (VTE). OBJECTIVES: We aimed to validate a new cancer-associated thrombosis (CAT) risk score in a population-based healthcare setting. METHODS: We used healthcare registry data and electronic medical records from the Central Denmark Region to calculate the new CAT risk score and the guideline-recommended Khorana score in patients with a first-time cancer diagnosis who initiated systemic cancer therapy. Patients were followed for 6 months after initiation of therapy. The outcome was any VTE identified through hospital discharge diagnoses. Discrimination was assessed using C statistics. RESULTS: We included 12 471 patients from 2012 to 2020. Of these, 416 (3.3%) developed VTE. The C statistic was 0.71 (95% CI, 0.68-0.74) for the new CAT score and 0.66 (95% CI, 0.63-0.70) for the Khorana score. The 6-month cumulative VTE incidence was 5.0% in 6175 patients classified as high risk by the new CAT score compared with 1.7% in 6296 patients classified as low risk. The 6-month cumulative VTE incidence was 5.2% in 4263 patients classified as high risk by the Khorana score compared with 2.4% in 8208 patients classified as low risk. CONCLUSION: The new CAT score had a discriminatory ability similar to that reported in the derivation study. The C statistic was numerically higher than that of the Khorana score. Our findings support the implementation of the new CAT score to identify ambulatory patients with cancer who are at high risk of VTE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsVenous ThromboembolismDecision Support TechniquesHumansRisk AssessmentFemaleMaleMiddle AgedAgedDenmarkRisk FactorsRegistriesIncidenceAdultReproducibility of ResultsPredictive Value of TestsTime FactorsAged, 80 and over

Stichwörter der Autor:innen

neoplasmsrisk assessmentvenous thrombosis

Autor:innen und Institutionen

  • Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands; Internal Medicine, Tergooi MC, Hilversum, the Netherlands; D…
  • Department of Clinical Epidemiology and Center for Population Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Medicine and Ageing Sciences, "G D'Annunzio" University, Chieti, Italy.
  • Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands; Internal Medicine, Tergooi MC, Hilversum, the Netherlands.

Förderung

  • Independent Research Fund Denmark
  • Karen Elise Jensens Fond

Zitieren

APA

Lanting, V., Vágó, E., Horváth-Puhó, E., Mulder, F., Di Nisio, M., Kamphuisen, P. W., Pedersen, L., van Es, N., & Sørensen, H. T. (2025). Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.10.021

Vancouver

Lanting V, Vágó E, Horváth-Puhó E, Mulder F, Di Nisio M, Kamphuisen PW, et al. Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2024.10.021

BibTeX
@article{Lanting2025,
  author = {Lanting, Vincent and Vágó, Emese and Horváth-Puhó, Erzsébet and Mulder, Frits and Di Nisio, Marcello and Kamphuisen, Pieter W and Pedersen, Lars and van Es, Nick and Sørensen, Henrik T},
  title = {Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2024.10.021}
}
Kostenlos starten →